MHH-Bibliothek

Alpharetroviral self-inactivating vectors produced by a superinfection-resistant stable packaging cell line allow genetic modification of primary human T lymphocytes

GND
1077263783
Affiliation
Medizinische Hochschule Hannover, Institut für Experimentelle Hämatologie
Labenski, Verena;
GND
1025264444
Affiliation
Medizinische Hochschule Hannover, Institut für Experimentelle Hämatologie
Sürth, Julia Debora;
Affiliation
Medizinische Hochschule Hannover, Institut für Experimentelle Hämatologie
Barczak, Elke;
GND
1015426832
ORCID
0000-0003-4047-975X
Affiliation
Medizinische Hochschule Hannover, Pädiatrische Hämatologie und Onkologie, Helmholtz-Zentrum für Infektionsforschung Braunschweig
Heckl, Dirk;
ORCID
0000-0002-0161-1765
Affiliation
CIRI, EVIR team France
Levy, Camille;
ORCID
0000-0002-2102-8198
Affiliation
CIRI, EVIR team France
Bernadin, Ornéllie;
Affiliation
Helmholtz-Zentrum für Infektionsforschung Braunschweig
Charpentier, Emanuelle;
Affiliation
Harvard Medical School Division of Hematology/Oncology, Boston Children’s Hospital, Harvard Medical School, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston
Williams, David A.;
GND
143740997
ORCID
0000-0001-9780-7211
Affiliation
University Medical Centre Hamburg-Eppendorf Research Department Cell and Gene Therapy, Dept. of Stem Cell Transplantation
Fehse, Boris;
GND
122620240
ORCID
0000-0001-9224-5491
Affiliation
CIRI, EVIR team, Inserm, Centre Méditerranéen de Médecine Moléculaire (C3M), équipe “contrôle métabolique des morts cellulaires”
Verhoeyen, Els;
GND
128643250
ORCID
0000-0003-2743-0070
Affiliation
Medizinische Hochschule Hannover, Institut für Experimentelle Hämatologie, Harvard Medical School, Boston
Schambach, Axel

Primary human T lymphocytes represent an important cell population for adoptive immunotherapies, including chimeric-antigen and T-cell receptor applications, as they have the capability to eliminate non-self, virus-infected and tumor cells. Given the increasing numbers of clinical immunotherapy applications, the development of an optimal vector platform for genetic T lymphocyte engineering, which allows cost-effective high-quality vector productions, remains a critical goal. Alpharetroviral self-inactivating vectors (ARV) have several advantages compared to other vector platforms, including a more random genomic integration pattern and reduced likelihood for inducing aberrant splicing of integrated proviruses. We developed an ARV platform for the transduction of primary human T lymphocytes. We demonstrated functional transgene transfer using the clinically relevant herpes-simplex-virus thymidine kinase variant TK.007. Proof-of-concept of alpharetroviral-mediated T-lymphocyte engineering was shown in vitro and in a humanized transplantation model in vivo. Furthermore, we established a stable, human alpharetroviral packaging cell line in which we deleted the entry receptor (SLC1A5) for RD114/TR-pseudotyped ARVs to prevent superinfection and enhance genomic integrity of the packaging cell line and viral particles. We showed that superinfection can be entirely prevented, while maintaining high recombinant virus titers. Taken together, this resulted in an improved production platform representing an economic strategy for translating the promising features of ARVs for therapeutic T-lymphocyte engineering.

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

Use and reproduction: